MedTrace Logo

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

NCT06511570 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-10-18

No results posted yet for this study

Summary

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Conditions

  • Alzheimer Disease

Interventions

DRUG

sabirnetug (ACU193)

sabirnetug by intravenous infusion

COMBINATION_PRODUCT

Sabirnetug + rHuPH20

sabirnetug + rHuPH20 by subcutaneous injection

Sponsors & Collaborators

  • Acumen Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Eric Siemers, M.D. · Acumen Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-25
Primary Completion
2024-09-17
Completion
2024-09-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06511570 on ClinicalTrials.gov